CVS division enters liquidation sale after $1 billion lawsuit
CVS just posted strong numbers, talked up billions in revenue, and sounded pretty confident about the future. But tucked behind all that good news, one of its divisions is heading into a liquidation sale after getting hit with nearly a $1 billion judgment. Let’s look into what is actually happening on that front.
The billion-dollar issue
At first glance, CVS looks solid. The company reported strong earnings and solid cash flow, with expectations of at least $400 billion in revenue for 2026.
Leadership sounded optimistic, with CEO David Joyner saying, “We still have an incredible amount of earnings power to unlock across our diversified business, but our progress to date has been impressive.”
However, Omnicare, the division that handles bulk medications for nursing homes and care facilities, is quietly unraveling in the background.
The company owned by CVS since 2015 filed for Chapter 11 back in September 2025. Now it is moving toward a court-ordered bankruptcy sale scheduled for May.
It all started with a whistleblower case, in which the division got hit with a nearly $1 billion judgment. Omnicare was accused of billing the U.S. government for drugs tied to invalid prescriptions, including medications dispensed to elderly and disabled patients in care facilities. Per TheStreet, there were over 3.3 million false claims between 2010 and 2018.
A federal judge ordered the unit to pay $542 million in penalties and $406.8 million in damages. That’s a total of $948.8 million.
Why CVS is staying quiet about it
Neither the CEO nor CFO really highlighted Omnicare during earnings. And that’s likely intentional. Clearly, this is being treated as a contained fire, not a company-wide crisis.
This makes sense, as CVS still owns a massive retail, insurance, and pharmacy ecosystem. Compared to that scale, Omnicare is just one piece, even if it’s a very expensive one.
Source: TheStreet